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The objective of this study is to design biodegradable hydrogels of gelatin for the controlled release 
of bioactive small interfering RNA (siRNA). Gelatin was cationized by chemically introducing 
ethylene diamine into the carboxyl groups in different conditions to obtain cationized gelatins (CGs). 
The CG was mixed with siRNA at various mixing ratios of amino groups of gelatin to the phosphate 
groups of siRNA in aqueous solution to form the siRNA-CG nano-complex. Gelatin together with 
the complex of siRNA and CG was chemically crosslinked to prepare the gelatin hydrogel 
incorporating the complex. The hydrogel incorporating the siRNA-CG complex was not degraded in 
phosphate-buffered saline solution (PBS) at 37 °C and did not release the siRNA complex after 
initial siRNA release and hydrogel degradation. When placed in PBS containing collagenase, the 
hydrogel was enzymatically degraded to release the siRNA complex. In this release system, the 
siRNA was released as a result of hydrogel degradation. The siRNA released showed an activity to 
specifically suppress the expression of the corresponding gene. The hydrogel is promising to release 
siRNA and also elicit biological activity for a longer time.  
 





 RNA interference (RNAi) is a biological phenomenon to turn off gene expression by directing 
degradation of the targeting mRNA, which was discovered in 1998 (Fire et al., 1998). Small 
interfering RNA (siRNA) is a short double-strand RNA of average only 21 - 23 base pairs which can 
induce RNAi (Zamore et al., 2000). Since siRNA can specifically inhibit the expression of target 
genes, the applications are widely being expected, for example, experimental tools to suppress gene 
expression in the sequence-specific manner (Gilbert et al., 2011; Tuzmen et al., 2011) and 
molecular-targeted therapy to inhibit the expression of pathogenic proteins related to cancer and viral 
infections (Gong et al., 2005; Rye et al., 2004). However, siRNA alone cannot always induce RNAi 
phenomena because of the low cell interaction and the low stability in the body. To effectively use 
siRNA-based gene suppression as both experimental and therapeutic tools, some technologies and 
methodologies should be established. Virus vectors have a high gene transfection efficiency and the 
long-term maintenance of gene expression (Xia et al., 2002), but the safety seems to be a major problem 
(Marshall 2002). Compared to the viral vectors, the non-viral vectors are relatively safe, however they 
need more enhancements for efficient introduction of genes into the target cells. Physical stimulation (e.g. 
electroporation (Reed et al., 2009), sonoporation (Newman et al., 2007), and iontophoresis 
(Andrieu-Soler et al., 2006)) enhanced the efficacy of gene transfection, although the technology is costly. 
To effectively use siRNA-based gene silencing as both the experimental and therapeutic tools, the level 
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and duration of gene silencing need to be optimized. 
 Drug delivery system (DDS) is one of the practically possible technologies to positively modify the 
biological activity of several drugs by combination of a drug and the carrier. Gelatin is a biocompatible 
protein which can be obtained through an alkaline, acid or enzymatic processing of animals’ collagen. 
Gelatin has various side chains (e.g. amino and carboxyl groups) which can be chemically modified with 
ease. Dehydrothermal or chemical treatment enables gelatin to intermolecularly crosslink for the hydrogel 
formation. Gelatin hydrogel is generally degraded by enzymes, such as collagenase and gelatinase of 
matrix metalloproteinases (MMPs) (Egeblad et al., 2002) and the hydrogel degradability can be changed 
by altering the crosslinking conditions. We have designed various hydrogels of DDS carriers with gelatin 
and the chemical derivatives to release biologically active substances, such as basic fibroblast growth 
factor (Tabata et al., 2000), bone morphogenetic protein 2 (Kimura et al., 2010), and transforming growth 
factor –1 (Holland et al., 2004), plasmid DNA (Kushibiki et al., ; Lin et al., 2009), siRNA (Matsumoto 
et al., 2006), or low molecular compounds (Tanigo et al., 2010). 
 The objective of this study is to create a gelatin hydrogel system for the controlled release of bioactive 
siRNA. Cationized gelatin (CG) was prepared to form the polyion complex of siRNA. The complex was 
mixed with gelatin, followed by chemical crosslinking to prepare gelatin hydrogels incorporating the 
complex of siRNA and CG. The siRNA release profile from the hydrogel was investigated while the 
activity of siRNA released was evaluated. 
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2. Materials and Methods 
2.1. Materials 
 Gelatin with an isoelectric point (pI) of 5.0 (Mw=100,000), prepared through an alkaline process of 
bovine bone (pI5 gelatin) or with a pI of 9.0 (Mw=100,000), prepared through an acid process of pig 
skin (pI9 gelatin) and collagenase L were kindly supplied from Nitta Gelatin Co., Osaka, Japan. The 
nucleotide sequences of siRNA targeted at the firefly luciferase gene (Luc siRNA) (Forward) 5’- 
CUUACGCUGAGUACUUCGATT -3’ and (Reverse) 5’- UCGAAGUACUCAGCGUAAGTT -3’ 
was purchased from B-Bridge International (Sunnyvale, CA, USA). All reagents were obtained from 
Nacalai Tesque, Kyoto, Japan except as indicated otherwise. 
 
2.2. Preparation of Luc siRNA and cationized gelatin complexes 
 The cationized gelatins (CGs) with different cationization extents were prepared as described 
previously (Saito et al., 2012). Briefly, various amounts of ethylenediamine (EDA) were added into 
25 ml of 0.1 M phosphate-buffered solution (PB, pH=5.0) containing 1.0 g of pI9 gelatin. The 
solution pH was adjusted to 5.0 by adding 6 M HCl aqueous solution, and PB was added into the 
solution to give the final volume of 50 ml. Then, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) was added into the solution, followed by the agitation at 37 °C for 4 hr and 
dialysis against double-distilled water (DDW) for 3 days at room temperature. The dialyzed solution 
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was freeze-dried to obtain CGs. Table 1 summarizes the molar percentage of EDA introduced to the 
carboxyl groups of gelatin. Next, the complexation of Luc siRNA and CG was performed by simply 
mixing at various mixing ratios of amino group number of CG per the phosphate group number of 
Luc siRNA (N/P) in aqueous solution. Briefly, deionized and sterilized water (RNase-free, DSW) 
containing different amounts of CG was slowly added to the same volume of 100 mM 
phosphate-buffered saline solution (PBS, pH=7.4) containing 10 nM of Luc siRNA at N/P mixing 
ratios of 1, 5, 10, 20, 30, and 50. The mixed solution was gently agitated at 37 °C for 10 min to form 
Luc siRNA and CG complexes. Table 1 summarizes the amount of CG against 1 M of Luc siRNA 
at N/P ratio 10. The CGs were sterilized by ethylene oxide gas (EOG) on a EOGelk SA-360ECO 
(ELK corporation, Osaka, Japan) before using. 
 
2.3. Dynamic light scattering and zeta potential measurements of CG complexes with Luc 
siRNA 
 To evaluate the nanocomplex size and zeta potential of CG and the Luc siRNA complexes, dynamic 
light scattering (DLS) and electrophoretic light scattering (ELS) measurements were carried out as 
described previously (Saito et al., 2012). The DLS measurement was carried out on 
aDLS-DPA-60HD (Otsuka Electronic Co.Ltd., Osaka, Japan) equipped with a He–Ne laser at a 
detection angle of 90 ° at 37 °C. ELS (ELS-7000, Otsuka Electronic Co. Ltd., Osaka, Japan) was 
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measured at room temperature and an electric field strength of 100 V/cm. The experiment was done 
three times independently for every sample unless otherwise mentioned. 
2.4. Cytotoxicity evaluation of CG 
 A luciferase-expressing cell line derived from colon 26 (Colon26-Luc) was kindly supplied by Dr. 
Takakura of Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan. The 
Colon26-Luc cells were cultivated in the Dulbecco’s modified Eagle medium (DMEM) containing 
10 vol% fetal bovine serum (FBS) and 1.0 vol% penicillin and streptomycin (DMEM-FBS) at 37 °C 
in a 95% air–5% CO2 atmosphere. The cytotoxicity of CG was evaluated by an in vitro bioassay as 
described previously (Saito et al., 2012) with minor modification. Briefly, Colon26-Luc cells were 
seeded into each well of 96-well multi-well culture plate (Corning Inc., NY, USA) at a density of 
5,000 cells (100 l) per well for 24 hr. And then, the medium was exchanged to 90 l of fresh 
medium and 10 l of CG aqueous solution, and 24 hr later, 
2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST-8) of 
cell count reagent SF (Nacalai Tesque, Kyoto, Japan) (10 l) was added into each well followed by 
incubation further for 30 min. The absorbance of medium was measured at 450 nm by the 
VERSAmax microplate reader (Molecular Devices, Sunnyvale CA, USA). The percentage of cell 
viability was expressed as 100 % for cells cultured without gelatin. The experiment was done 5 
times independently for each sample. 
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2.5. Evaluation of gene suppression of Luc siRNA and CG complexes 
 Gene suppression with Luc siRNA and CG complexes were evaluated according to the method 
reported previously (Nagane et al., 2009). Colon26-Luc cells were seeded into each well of 12-well 
multi-well culture plate (Corning Inc., NY, USA) at a density of 50,000 cells (1.0 ml) per well in the 
DMEM. After 24 hr incubation, the medium was removed, and the well was washed by PBS (1.0 ml) 
twice. Then, Opti-MEM I Reduced-Serum Medium (Opti-MEM, Life Technologies Japan Ltd., 
Osaka, Japan) of gene transfection medium (450 l) and the complex solution of Luc siRNA at 
different concentrations of CG (50 l) were added into each well, followed by 6 hr incubation. After 
rinsing with PBS, cells were continued to culture in DMEM-FBS further for 0, 18, and 42 hr. To 
evaluate the biological activity of Luc siRNA, cells were washed with PBS twice, lysed in 100 l of 
cell-culture lysis reagent (Promega KK, Osaka, Japan). Then, 100 l luciferase assay reagent 
(Promega KK, Osaka, Japan) was added to 10 l of supernatant while the relative light unit (RLU) 
of the samples was determined by a luminometer (MicroLumatPlus LB 96V, Berthold, Tokyo, 
Japan). The total protein content in each well was determined by micro bicinchonic acid (BCA) 
protein assay kit (Pierce, Rockford, IL, USA) according to the manufacturers’ instructions to 
normalize the influence of number variance of cells on the luciferase activity. Each experimental 




2.6. Preparation of gelatin hydrogels incorporating Luc siRNA and CG complexes 
 To prepare the complex of Luc siRNA and CG, Luc siRNA (10 nmole/ml, 100 l) was mixed with 
various N/P ratios of CG in DSW (100 l) at 37 °C. Next, aqueous solution of pI5 gelatin (20 wt%, 
200 l) was added to the complex solution at 37 °C. Then, the solution was mixed with 25 wt% of 
glutaraldehyde (2.5 l) at a concentration of 0.63 vol%, and cast into a polypropylene dish (1.0 
mm×1.0 mm, Sakura Finetek Japan Co., Ltd., Tokyo, Japan), followed by leaving at 4 °C for 8 hr for 
chemical crosslinking of gelatin. The hydrogels were agitated in 100 mM glycine solution at 37 °C 
for 1 hr to block the residual aldehyde groups of glutaraldehyde. Following 1 hr washing three times 
with DSW, the hydrogels were freeze-dried to obtain the gelatin hydrogels incorporating Luc siRNA 
and CG complex. 
 
2.7. Release test of Luc siRNA from gelatin hydrogels incorporating Luc siRNA and CG 
complexes 
 Hydrogels of 5.0 to 7.0 mg in dry weight were placed in PBS (500 l) at 37 °C. The PBS 
supernatant was exchanged 1, 2, 4, 8, 24, 48, and 96 hr later and subsequently the hydrogels were 
completely degraded by PBS containing collagenase (5.0 g/ml, 500 l). The release test was 
performed in PBS for the initial 24 hr and after that done in PBS containing collagenase (5.0 g/ml). 
The amount of Luc siRNA in solution sampled was determined by the conventional method of 
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ethidium bromide (Et-Br) with fluorescence spectrometry (Le Pecq et al., 1966). Briefly, Et-Br was 
dissolved in 0.1 M NaCl and 0.1 M tris (hydroxymethyl) aminomethane aqueous solution (10 g/ml). 
The Et-Br solution (150 l) and sample solution (150 l) were mixed in each well of 96-well 
multi-well culture black plate (Corning Inc., NY, USA) A calibration curve was prepared with the 
determined amounts of Luc siRNA. Fluorescence spectra were measured at room temperature on a 
SpectraMax Gemini EM (Molecular Device, Osaka, Japan) at the excitation and emission 
wavelengths of 546 and 596 nm, respectively. The percent introduced was determined based on the 
calibration curve and the fluorescence of samples. The experiment was done three times 
independently for every sample unless otherwise mentioned. 
 
2.8. Degradation evaluation of hydrogels incorporating Luc siRNA and CG complex 
 Hydrogels of 5.0 to 7.0 mg in dry weight were placed in PBS (500 l) at 37 °C. The PBS 
supernatant was exchanged 1, 2, 4, 8, and 24 hr later and subsequently PBS containing collagenase 
(5.0 g/ml) was added. PBS containing collagenase supernatant was exchanged every 3 hr and fresh 
one was added. The amount of gelatin solution sampled was determined by micro BCA protein assay 





2.9. Evaluation of gene suppression experiments of Luc siRNA released from hydrogels 
 The hydrogel of 5.0 to 7.0 mg in dry weight was placed in Opti-MEM (1.0 ml) at 37 °C. The 
Opti-MEM supernatant was collected 24 hr later, and then 1.0 ml of Opti-MEM containing 
collagenase (5.0 g/ml, Opti-MEM-col) was added. The Opti-MEM-col was exchanged 3, 6, 9, and 
12 hr later to collect the supernatant. The hydrogel was gradually degraded in Opti-MEM-col with 
time to release the Luc siRNA incorporated. The amount of gelatin in the supernatant sampled was 
determined by the micro BCA protein assay described above. The Luc siRNA concentration of 
supernatant sampled was determined by the Et-Br fluorescence spectrometry described above. The 
gene suppression activity of Luc siRNA in the supernatants collected, was performed according to 
the method previously reported (Nagane et al., 2009). Briefly, Colon26-Luc cells were cultured in 
each well of 12-well multi-well culture plate at a density of 50,000 cells (1.0 ml) in the DMEM for 
24 hr at 37 °C in 5 % CO2–95 % air atmosphere. After washing of the well by PBS (1.0 ml) twice, 
the supernatant of Opti-MEM or Opti-MEM-col (500 l) was added into each well, followed by 6 hr 
incubation. The luciferase and micro BCA protein assays were performed described above. As a 
control, the similar experiment for the complex of Luc siRNA freshly prepared at the same 
concentration as the supernatant collected at the corresponding N/P ratio and CG type was carried 




Suppression activity (%) = (100 – percent luciferase expression of supernatant) ×100 / (100 – 
percent luciferase expression of control complex) 
 
The experiment was done three times independently for every sample unless otherwise mentioned. 
 
2.10. Statistical analysis 
All the results were expressed as the mean ± standard deviation (SD). Significant analysis was done 
based on Fisher's least significant difference test for multiple comparisons, and the difference was 





3.1. Characterization of Luc siRNA and CG complexes 
Table 1 summarizes the preparation of CG and the complexes with Luc siRNA. Figure 1 shows the 
apparent molecular size and zeta potential of CG with different cationization extents and the Luc 
siRNA complexes. The molecular size of CGs and the Luc siRNA complex tended to reach to a 
certain value when the N/P ratio was higher than 10. The complexes size ranged from 100 to 300 nm 
at higher N/P ratios. The zeta potential of CGs and the Luc siRNA complexes tended to increase with 
the cationization extent of gelatin and N/P mixing ratio. 
 Figure 2 shows the cytotoxicity of CGs. CGs with lower extents of cationization showed no 
cytotoxicity. On the contrary, the E-7.0 and E-50 CGs showed cytotoxicity. Overall, the cytotoxicity 
increased with an increase in the CG amount. 
 
3.2. Gene suppression of Luc siRNA and CG complexes 
 Figure 3 shows the gene expression suppression of Luc siRNA and CG complexes. Higher 
suppression of gene expression was observed for the Luc siRNA complexes of E-7.0 and E-50 CGs 





3.3. In vitro time profiles of Luc siRNA release from gelatin hydrogels incorporating Luc 
siRNA and CG complexes 
 Figure 4 shows the in vitro time profiles of Luc siRNA release from gelatin hydrogels incorporating 
Luc siRNA and CG complexes in PBS with or without collagenase. About 35 % of Luc siRNA was 
released initially, but after that no release was observed. On the other hand, in PBS containing 
collagenase, the Luc siRNA was released similarly, irrespective of the CG type and N/P ratio. 
 
3.4. In vitro time profiles of hydrogel degradation 
Figure 5 shows in vitro time profiles of gelatin hydrogel degradation in PBS with or 
without collagenase. About 29 % of hydrogel was degraded initially, but after that no 
degradation was observed. On the other hand, in PBS containing collagenase, the hydrogel was 
degraded similarly, irrespective of the CG type and N/P ratio. 
 
3.5. Gene suppression activity of Luc siRNA released 
 Figure 6 shows the gene suppression activity of medium supernatants after culture with hydrogels 
incorporating Luc siRNA and CG complex. The Opti-MEM supernatant did not show the 
suppression activity of gene expression (Figure 6 (b)) irrespective of the N/P ratio and CG type. On 
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the contrary, the Opti-MEM-col supernatant had significant suppression activity (Figure 6 (a)). The 
suppression activity for gelatin hydrogels incorporating Luc siRNA and CG complexes at the N/P 
ratio of 50 had significantly higher than that of hydrogels at the N/P ratio of 10 (Figure 6 (c). Even 
after 3, 6, and 9 hr incubation in Opti-MEM-col, the supernatants showed significant gene 
suppression activity (Figure 6 (d)). However, after 12 hr incubation in Opti-MEM-col, any 
supernatant did not show gene suppression activity because the amount of Luc siRNA in the 
supernatant was very low (data not shown). Table 3 summarizes the amount of Luc siRNA released 
from gelatin hydrogels in Opti-MEM-col. Luc siRNA was gradually released from gelatin hydrogel 





The present study demonstrates that the biological activity of siRNA was associated with the 
release rate of siRNA from the hydrogel and to the enzymatic degradation of gelatin hydrogels. 
Gelatin and the derivatives have been used to prepare the hydrogel of carrier material for the 
controlled release of various drugs (Tanigo et al., 2010), proteins (Kohara et al., 2011; 
Ratanavaraporn et al., 2011), and genes (Doi et al., 2011; Kushibiki et al., 2004; Lin et al., 2009; 
Matsumoto et al., 2006), because of the biodegradability and biocompatibility. When the siRNA was 
directly incorporated into the hydrogels prepared by the chemical crosslinking of pI5 or pI9 gelatin, 
an initial burst in siRNA release (about 80 %) was observed (data not shown). For hydrogels 
prepared from pI5 gelatin (5 wt%), an initial burst in siRNA release (34.3 to 53.4 %) was observed 
(Supplementary Figure 1). This is because the siRNA molecules do not always interact with the 
gelatin molecules, resulting in the burst release by the simple diffusion of siRNA. One of the 
methods to enhance the interaction of siRNA with gelatin is to use the cationized derivative which 
can electrostatically interact with negatively charged siRNA. The hydrogel of cationized gelatin 
worked well to achieve the controlled release of siRNA in vivo (Obata et al., 2012). However, the 
cationized hydrogel sometimes induces severe inflammation reaction compared to the 
normal gelatin. Therefore, the siRNA of negative charge (phosphate group) was mixed with the 
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CG to form the nano-complex. Then, the complex was mixed with aqueous gelatin solution at a high 
concentration (20 wt%) to obtain the hydrogels. The complex of positive charge enabled the 
immobilization into the hydrogel of pI5 gelatin with a negative charge. In this release system, the 
siRNA is released in the complex form with the CG hydrogel only when the hydrogel is 
enzymatically degraded to generate water-soluble gelatin fragments. The siRNA activity to suppress 
the gene expression is high for the complex form compared with siRNA in the free form (Kim et al., 
2010). It is possible that the siRNA was released from the hydrogel in the form of complex with CG. 
CG will accelerate the cellular internalization of siRNA, resulting in the enhanced gene suppression 
activity. 
Several researchers investigate the carrier for the sustained release of gene in vitro (Jensen et al., 
2012; Krebs et al., 2009; Nelson et al., 2012) and in vivo (Jacobson et al., 2010; Lobovkina et al., 
2011). For example, the hydrogels of photo-crosslinked alginate and collagen achieved the sustained 
delivery of siRNA (Krebs et al., 2009). The 3-dimensional hydrogels for sustained delivery of 
siRNA could suppress gene expression for 6 days in vitro. In addition, the in vivo sustained release 
of siRNA could be achieved with solid lipid nanoparticles (Lobovkina et al., 2011). The present 
hydrogel system is applicable for the sustained release of siRNA as a result of enzymatic hydrogel 
degradation. The release profiles of siRNA were in consistence with the rate of hydrogel degradation. 
This again supports the release of siRNA in the complex form with the degraded fragment of CG. In 
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the case of in vitro and in vivo controlled siRNA release study, the hydrogel system can be changed 
the release profile by using different concentration of collagenase solutions or different crosslinking 
extent of the hydrogels. The time period of hydrogels degradation ranged from a few days to several 
months (Tabata et al., 1999).These controlled gene silencing technologies have significant potential 
for use in tissue regeneration applications and experimental tools for suppression of specific gene 
expression. 
The key factor to consider the siRNA action is not only the extent of gene silencing, but also the 
time period of activity maintenance. Even if the siRNA can be released, the release of inactive 
siRNA is practically useless. Therefore, in this study, the gene suppression activity of supernatants 
after the placement of hydrogel in the Opti-MEM-col was assessed (Figures 6 (a-d)). When placed in 
Opti-MEM-col, it is likely that the hydrogel was degraded to release the Luc siRNA complex 
incorporated in the hydrogel. When compared at the same siRNA concentration, the supernatant 
containing the complex released exhibited significant gene suppression activity although the activity 
was low compared with the fresh complex as a control. siRNA released from gelatin hydrogels 
incorporating Luc siRNA and CG complex (N/P ratio 50) showed higher transfection efficacy than 
those of CG at the N/P ratio of 10. It is highly conceivable that during enzymatic degradation, the 
hydrogel gelatin and CG for the complexation with siRNA were randomly degraded. However, the 
siRNA activity in the supernatant after hydrogel incubation in the Opti-MEM-col remained. It is 
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highly conceivable that even by enzymatic degradation, the siRNA itself was not degraded because 
of the complexation. The siRNA would be released in the complex form. In conclusion, the 
biodegradable hydrogel of gelatin is a promising carrier for the siRNA release which is driven by the 
hydrogel degradation. The Opti-MEM-col supernatants showed an activity to suppress the 
expression of the corresponding gene. By using the hydrogel, the biological activity of siRNA can be 
retained for a long time period. 
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Table 1. Preparation of CG for complexation with Luc siRNA 
Code Gelatin concentration EDA concentration EDA used Percentage Amount of CG  
  (g/ml) (ml) molar ratioa of EDA introducedb used for complexationc (mg/ml) 
E-1.0 1.0 0.063   1.0 16.7±1.8 9.87 
E-3.0 1.0 0.188   3.0 27.0±2.8 8.35 
E-7.0 1.0 0.439   7.0 36.0±1.2 7.37 
E-50 1.0 3.14  50 56.5±4.5 5.80 
 a The molar ratio of EDA added to the carboxyl groups of gelatin 
 b The molar percentage of EDA introduced to the carboxyl groups of gelatin 





Table 2. The amount of Luc siRNA released in Opti-MEM with or without collagenase 
Code Luc siRNA released in Opti-MEM (nM) 
  without collagenase with collagenase 
E-7.0, N/P = 10 85.3 ± 10.5 126.9 ± 16.7 
E-7.0, N+P = 50 75.0 ±  5.7 120.0 ± 24.5 
E-50, N/P = 10 76.3 ±  0.72 117.5 ± 43.8 





Table 3. The amount of Luc siRNA released in Opti-MEM contains collagenase 
Time (hr) 
E-7.0 (nM)   E-50 (nM) 
N/P = 10 N/P = 50   N/P = 10 N/P = 50 
3  27.3±2.3 27.7±6.7   37.9±1.5 22.4±3.8 
6  32.0±3.3 32.4±6.3   35.5±4.7 27.1±7.6 
9  13.2±2.9 6.2±4.5   11.6±7.7 15.9±6.3 





Figure 1. Apparent molecular sizes (A) and zeta potentials (B) of Luc siRNA and CG complexes. The complexes 
were prepared for 1.0 (○), 10, (△), and 100 nM (□) of Luc siRNA with E-1.0 (a), E-3.0 (b), E-7.0 (c), and E-50 
CGs (d) in DDW at 37 °C.  
  
Figure 2. Cytotoxicity of CGs with different cationization extents. Colon26-Luc cells were cultured in the fresh 
medium containing CG at concentrations of 0.1 (□), 1.0 (■), and 10 nM (■) for 24 hr. The percentage of cell 
viability was expressed as 100 % for cells cultured in fresh medium containing pI9 gelatin. *, P<0.05; significant 
against the viability of cells cultured in the medium containing pI9 gelatin. 
 
Figure 3. Gene suppression of Luc siRNA and CG complexes. The complexes were prepared for 100 
nM of Luc siRNA with E-1.0 (a), E-3.0 (b), E-7.0 (c), and E-50 CGs (d) in DSW at the N/P ratio of 1 
(□), 5 (■), 10 (■), 20 (  ), 30 (  ), and 50 (  ). *, P<0.05; significant against the gene expression of 
colon26-Luc without Luc siRNA. 
   
Figure 4. In vitro release profiles of Luc siRNA from gelatin hydrogels incorporating complexes of Luc siRNA and 
CG without collagenase (a and b). The complexes were prepared for siRNA with E-1.0 (○), E-3.0 (●), E-7.0 (□), 
and E-50 CGs (■). The N/P ratios are 10 (a) and 50 (b). (c) In vitro release profiles of Luc siRNA from gelatin 
hydrogels incorporating complexes of Luc siRNA and E-7.0 CG at N/P ratios of 10 (○) and 50 (●) and E-50 CG, 
at N/P ratios of 10 (□) and 50 (■). The release test was performed in PBS for the initial 24 hr, and thereafter in 
35 
 
collagenase PBS solution (5 g/ml) indicated by hr arrow at 37 °C. 
 
Figure 5. In vitro degradation profiles of gelatin hydrogels incorporating complex of siRNA and E-7.0, at N/P 
ratios of 10 (○) and 50 (●) and E-50 CG, at N/P ratios of 10 (□) and 50 (■). The degradation test was performed 
in PBS for the initial 24 hr, and thereafter in collagenase PBS solution (5 g/ml) indicated by hr arrow at 37 °C.  
 
Figure 6. Percent gene expression of Luc siRNA released from gelatin hydrogels incorporating Luc siRNA and CG 
complexes in Opti-MEM with (a) and without collagenase (b). Gene suppression of fresh Luc siRNA and CG 
complex (□) and the supernatant (■) 24 hr after incubation with hydrogels incorporating complex in Opti-MEM. 
*, P<0.05; significant between the two groups. (c) Percent suppression activity calculated by the formulation 
described above. *, P<0.05; significant between the two groups. (d) Percent gene expression of Luc siRNA 
released from gelatin hydrogels incorporating Luc siRNA and CG complexes in Opti-MEM with collagenase. The 
supernatant was collected 3 (□), 6 (■), and 9 hr (■) after culturing with the hydrogels incorporating complex to 
check the gene suppression activity. *, P<0.05; significant against the gene expression of colon26-Luc without Luc 
siRNA. The percentage of luciferase expression was expressed as 100 % for colon26-Luc cultured in Opti-MEM 





















































































































































































































































































































































































































































































































































































Supplementary Figure 1. In vitro release profiles of Luc siRNA from gelatin hydrogels 
incorporating complexes of Luc siRNA and CG. The complexes were prepared for siRNA 
with E-1.0 (○), E-3.0 (●), E-7.0 (□), and E-50 CG (■). The N/P ratio is 50. 
 
